Russo, V.; Attena, E.; Rago, A.; Melillo, E.; Di Micco, P.; Papa, A.A.; Napolitano, G.; D’Onofrio, A.; Golino, P.; Nigro, G.
Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study. J. Clin. Med. 2020, 9, 1621.
https://doi.org/10.3390/jcm9061621
AMA Style
Russo V, Attena E, Rago A, Melillo E, Di Micco P, Papa AA, Napolitano G, D’Onofrio A, Golino P, Nigro G.
Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study. Journal of Clinical Medicine. 2020; 9(6):1621.
https://doi.org/10.3390/jcm9061621
Chicago/Turabian Style
Russo, Vincenzo, Emilio Attena, Anna Rago, Enrico Melillo, Pierpaolo Di Micco, Andrea Antonio Papa, Giovanni Napolitano, Antonio D’Onofrio, Paolo Golino, and Gerardo Nigro.
2020. "Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study" Journal of Clinical Medicine 9, no. 6: 1621.
https://doi.org/10.3390/jcm9061621
APA Style
Russo, V., Attena, E., Rago, A., Melillo, E., Di Micco, P., Papa, A. A., Napolitano, G., D’Onofrio, A., Golino, P., & Nigro, G.
(2020). Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study. Journal of Clinical Medicine, 9(6), 1621.
https://doi.org/10.3390/jcm9061621